REVIEW ARTICLE
Obstetrics and Gynecology
doi: 10.25005/2074-0581-2026-28-1-122-139
EFFICACY OF INOSITOLS IN POLYCYSTIC OVARY SYNDROME AND GESTATIONAL DIABETES MELLITUS: ANALYSIS OF PATHOGENETIC AND CLINICAL DATA

A.A. DRUZHININA1, S.M. GIULAKHMEDOVA1, O.S. ALYAUTDINA2, F. BASHOKOUH3, E.M. ELISEEVA1, A.A. CHISTOKHINA1

1Scientific Centre for Expert Evaluation of Medicinal Products, Moscow, Russian Federation
2Sechenov First Moscow State Medical University, Moscow, Russian Federation
3Iran Food and Drug Administration, Drugs and Controlled Medicines Division, Tehran, Iran

Infertility is a common problem in the world, which has a significant negative social impact. An important factor that affects female reproductive function is insulin resistance which is common for such conditions as polycystic ovary syndrome (PCOS) and gestational diabetes mellitus (GDM). PCOS is caused by hormone imbalance leading to high levels of male hormones (androgens). Androgen excess has a number of physical manifestations and leads to fertility problems. GDM occurs in pregnant women, it is characterised by the development of spontaneous hyperglycaemia, which is a serious pregnancy complication. Currently, there are various approaches to addressing the causes of infertility, but there have not been any significant improvements in birth rates. Therefore, alternative pharmacotherapeutic options are being explored to improve health and fertility, which include the use of various natural substances and dietary supplements. One such promising compound is inositol, due to its potential benefits in reproductive therapy. Its main bioactive forms in living organisms are myo-inositol and D-chiro-inositol whose insulin-sensitising and anti-androgenic effects help to ameliorate metabolic dysfunctions and fertility problems in PCOS. Inositol has the ability to improve endocrine profile, restore ovulation, improve oocyte and sperm quality, reduce the risk of ovarian hyperstimulation syndrome during the use of assisted reproductive technologies, thereby increasing the chances of pregnancy. The present review of studies supports the efficacy of inositol, but further research and clinical trials are needed to generate more reliable evidence and get a better understanding of inositol mechanism of action.

An analysis was conducted of the results of fundamental and clinical studies on the use of MI for the treatment of diabetes mellitus, GDM, as well as in PCOS and reduced fertility, published in the databases Google Scholar, PubMed, Embase, Cochrane Library, CyberLeninka, and eLIBRARY.RU from 2015 to 2024. Earlier publications were also included in the narrative review. The search was performed using the keywords “inositol”, “myo-inositol”, “diabetes mellitus”, “gestational diabetes”, “polycystic ovary syndrome”, “hyperandrogenism”, and “spermatogenesis”.

Keywords: Myo-inositol, D-chiro-inositol, fertility, gestational diabetes mellitus, polycystic ovary syndrome, insulin resistance, infertility.

Download file:

References
  1. Rusanova NE. Infertility and fertility: Demographic problems of assisted reproduction. Population and Economics. 2024;8(1):156-67.
  2. Boivin J, Vassena R, Costa M, Vegni E, Dixon M, Collura B, et al. Tailored support may reduce mental and relational impact of infertility on infertile patients and partners. Reprod Biomed Online. 2022;44(6):1045-54. https://doi.org/10.1016/j. rbmo.2022.01.015
  3. Kurosawa Y, Nirengi S, Homma T, Esaki K, Ohta M, Clark JF, et al. A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles. Sci Rep. 2015;5:11601. https://doi.org/10.1038/srep11601
  4. Jiang D, Li L, Zeng BY. Treatment of Chinese herbal medicine for female infertility. Int Rev Neurobiol. 2017;135:233-47. https://doi.org/10.1016/bs.irn.2017.02.011
  5. Gromova O, Torshin I, Uvarova E, Tapilskaya N, Kalacheva A. Sistematicheskiy analiz biologicheskikh roley i farmakologicheskikh svoystv D-khiroinozitola [Systematic analysis of the biological roles and pharmacological properties of D-chiro-inositol]. Ginekologya. 2020;22(3):21-8.
  6. Ghaemi M, Seighali N, Shafiee A, Beiky M, Gargari OK, Azarboo A, et al. The effect of myo-inositol on improving sperm quality and IVF outcomes: A systematic review and meta-analysis. Food Sci Nutr. 2024;12(11):8515-24. https://doi. org/10.1002/fsn3.4427
  7. Li Y, Han P, Wang J, Shi T, You C. Production of myo-inositol: Recent advance and prospective. Biotech Appl Biochem. 2021;69(3):1101-11. https://doi. org/10.1002/bab.2181
  8. Belenkaia L, Lazareva L, Walker W, Lizneva D, Suturina L. Criteria, phenotypes and prevalence of polycystic ovary syndrome. Minerva Ginecologca. 2019;71(3):211- 23. https://doi.org/10.23736/S0026-4784.19.04404-6
  9. Dinicola S, Unfer V, Facchinetti F, Soulage CO, Greene ND, Bizzarri M, et al. Inositols: From established knowledge to novel approaches. Int J Mol Sci. 2021;22(19):10575. https://doi.org/10.3390/ijms221910575
  10. Metodicheskie rekomendatsii MP 2.3.1.0253-21 «Normy fiziologicheskikh potrebnostey v energii i pishchevykh veshchestvakh dlya razlichnykh grupp naseleniya Rossiyskoy Federatsii» [Methodological Recommendations MP 2.3.1.0253-21 “Norms of physiological needs for energy and nutrients for various population groups of the Russian Federation” [Internet]. Garant.ru. 2021. Available from: https://www.garant.ru/products/ipo/prime/doc/402716140/
  11. Vorontsova AV, Gasparyan SA, Gromova OA, Dzhobava EM, Kiselyova EYu, Korotkikh IN, i dr. Zaklyuchenie soveshchaniya ekspertov «Obosnovanie primeneniya sredstv na osnove inozitola u patsientok s narusheniyami menstrual'nogo tsikla» [The conclusion of the Expert Council “The product rationale based on inositol for use by patients with menstrual irregularities”]. Problemy reproduktsii. 2020;26(1):44-54.
  12. Khabarov SV, Andreevskaya TV. Inozitol: vliyanie na reproduktivnuyu sistemu (obzor literatury) [Inositol: Effects on the reproductive system (literature review)]. Vestnik novykh meditsinskikh tekhnologiy. 2024;31(1):44-9. https://doi. org/10.24412/1609-2163-2024-1-44-49
  13. Unfer V, Facchinetti F, Orrù B, Giordani B, Nestler J. Myo-inositol effects in women with PCOS: A meta-analysis of randomized controlled trials. Endocrine Connec- tions. 2017;6(8):647-58. https://doi.org/10.1530/EC-17-0243
  14. Kalacheva AG, Torshin IY, Stelmashuk EV, Genrikhs EE, Aleksandrova OP, Khaspekov LG, i dr. Neyroprotektornoe deystvie mioinozitola na kletochnoy modeli glutamatnogo stressa kak osnova dlya profilaktiki narusheniy vnutriutrobnogo razvitiya golovnogo mozga [Neuroprotective effect of myoinositol on a cellular model of glutamate stress as a basis for the prevention of intrauterine brain development disorders]. Farmakokinetika i farmakodinamika. 2018;3:9-20. https://doi.org/10.24411/2587-7836-2018-10018
  15. Bogachyova T, Gromova O, Torshin I. Sistematicheskiy analiz farmakologii mioinozitola i D-khiroinozitola [Systematic analysis of the pharmacology of myoinositol and D-chiroinositol]. Farmakokinetika i farmakodinamika. 2024;1:4- 13. https://doi.org/10.37489/2587-7836-2024-1-4-13
  16. Muscogiuri G, Palomba S, Laganà AS, Orio F. Erratum to “Inositols in the treatment of insulin-mediated diseases”. Int J Endocrinol. 2016;4;2016:1. https:// doi.org/10.1155/2016/6189820
  17. Chernukha GE, Udovichenko MA, Naydukova AA. Mekhanizmy formirovaniya insulinorezistentnosti pri sindrome polikistoznykh yaichnikov i terapevticheskie effekty mio-inozitola [Mechanisms of insulin resistance formation in polycystic ovarian disease and therapeutic effects from myo-inositol]. Doktor.Ru. 2019;166(11):55-60. https://doi.org/10.31550/1727-2378-2019-166-11-55-60
  18. Croze ML, Soulage CO. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. 2013;95(10):1811-27. https://doi.org/10.1016/j. biochi.2013.05.011
  19. Dinicola S, Unfer V, Facchinetti F, Soulage CO, Greene ND, Bizzarri M, et al. Inositols: From established knowledge to novel approaches. Int J Mol Sci. 2021;30;22(19):10575. https://doi.org/10.3390/ijms221910575
  20. Ghaemi M, Seighali N, Shafiee A, Beiky M, Gargari OK, Azarboo A, et al. The effect of myo‐inositol on improving sperm quality and IVF outcomes: A systematic review and meta‐analysis. Food Sci Nutr. 2024;12(11):8515-24. https://doi. org/10.1002/fsn3.4427
  21. Lei R, Chen S, Li W. Advances in the study of the correlation between insulin resistance and infertility. Front Endocrinol. 2024;26:15. https://doi.org/10.3389/ fendo.2024.1288326
  22. Absatarova YuS, Sheremetyeva EV, Andreeva EN. Vzaimosvyaz' somnologicheskikh i metabolicheskikh narusheniy pri sindrome polikistoznykh yaichnikov [The relationship between somnological and metabolic disorders in polycystic ovary syndrome]. Doktor.Ru. 2016;8-9:57-62.
  23. Shilova OYu, Gladkaya VS. Insulinorezistentnost' i narushenie reproduktsii (obzor literatury) [Insulin resistance and reproductive damage (literature review)]. Mat' i ditya v Kuzbasse. 2018;4:13-20.
  24. Silvestris E, de Pergola G, Rosania R, Loverro G. Obesity as disruptor of the female fertility. Reprod Biol Endocrinol. 2018;16(1):22. https://doi.org/10.1186/s12958- 018-0336-z
  25. Lee SH, Park SY, Choi CS. Insulin resistance: From mechanisms to therapeutic strategies. Diabet Metab J. 2021;46(1):15-37. https://doi.org/10.4093/ dmj.2021.0280
  26. Alyautdina OS, Prilutskaya VY, Krylova EI. Primenenie streoizomerov inozitola dlya terapii patsientok s klinicheskimi i biokhimicheskimi priznakami giperandrogenii [The use of inositol stereoisomers for the treatment of patients with clinical and biochemical signs of hyperandrogenism]. Arkhiv akusherstva i ginekologii im. V.F. Snegiryova. 2021;8(2):81-92. https://doi.org/10.17816/2313-8726-2021-8-2- 81-92
  27. Polycystic Ovary Syndrome [Internet]. www.who.int. Available from: www.who. int/ru/news-room/fact-sheets/detail/polycystic-ovary-syndrome
  28. Lazareva L, Sharifulin E, Belenkaya L, Suturina L. SPKYa v reproduktivnom vozraste: fenotipicheskoe raznoobrazie i diagnosticheskie podkhody (obzor literatury) [Polycystic ovary syndrome in women of reproductive age: Phenotypic variety and diagnostic approaches. Review of literature]. Doktor.Ru. 2020;19(6):50-6. https://doi.org/10.31550/1727-2378-2020-19-6-50-56
  29. Carlomagno G, Unfer V, Roseff S. The D-chiro-inositol paradox in the ovary. Fertil Steril. 2011;95(8):2515-6. https://doi.org/10.1016/j.fertnstert.2011.05.027
  30. Fornes R, Ormazabal P, Rosas C, Gabler F, Vantman D, Romero C, et al. Changes in the expression of insulin signaling pathway molecules in endometria from polycystic ovary syndrome women with or without hyperinsulinemia. Mol Med. 2010;16:129-36. https://doi.org/10.2119/molmed.2009.00118
  31. Bizzarri M, Fuso A, Dinicola S, Cucina A, Bevilacqua A. Pharmacodynamics and pharmacokinetics of inositol(s) in health and disease. Exp Opin Drug Metab Tox- icol. 2016;12(10):1181-96. https://doi.org/10.1080/17425255.2016.1206887
  32. Facchinetti F, Orrù B, Grandi G, Unfer V. Short-term effects of metformin and myo- inositol in women with polycystic ovarian syndrome (PCOS): A meta-analysis of randomized clinical trials. Gynecol Endocrinol. 2019;35(3):198-206. https://doi.or g/10.1080/09513590.2018.1540578
  33. Prilutskaya V, Alyautdina O, Sosna N. Vliyanie kombinatsii mioinozitola i D-khiroinozitola v sootnoshenii 5:1 na psikhoemotsional'noe sostoyanie i proyavleniya androgenzavisimoy dermopatii u patsientok s sindromom polikistoznykh yaichnikov [The effect of the combination of myoinositol and D-chiroinositol in a ratio of 5:1 on the psychoemotional state and manifestations of androgen-dependent dermopathy in patients with polycystic ovary syndrome]. Problemy reproduktsii. 2021;27(4):97‑107. https://doi. org/10.17116/repro20212704197
  34. Gilling-Smith C, Story H, Rogers V, Franks S. Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol (Oxf). 1997;47(1):93-9. https://doi.org/10.1046/j.1365-2265.1997.2321049.x
  35. Fedeli V, Unfer V, Dinicola S, Laganà AS, Canipari R, Monti N, et al. Inositol restores appropriate steroidogenesis in PCOS ovaries both in vitro and in vivo experimental mouse models. Cells. 2024;13(14):1171. https://doi.org/10.3390/ cells13141171
  36. Mazerkina I, Davydov I, Alyautdina O. Kombinirovannye oral'nye kontratseptivy pri sindrome polikistoznykh yaichnikov: pro i contra (obzor) [Combined oral contraceptives for polycystic ovary syndrome: Pro and contra (Review)]. Bezopas- nost' i risk farmakoterapii. 2024;12(2):214-29. https://doi.org/10.30895/2312- 7821-2024-12-2-214-229
  37. Ye W, Xie T, Song Y, Zhou L. The role of androgen and its related signals in PCOS. J Cell Mol Med. 2021;25(4):1825-37. https://doi.org/10.1111/jcmm.16205
  38. Nestler JE, Unfer V. Reflections on inositol(s) for PCOS therapy: Steps toward success. Gynecol Endocrinol. 2015;31(7):501-5. https://doi.org/10.3109/09513 590.2015.1054802
  39. Liao B, Qiao J, Pang Y. Central regulation of PCOS: Abnormal neuronal- reproductive-metabolic circuits in PCOS pathophysiology. Front Endocrinol. 2021;12:667422. https://doi.org/10.3389/fendo.2021.667422
  40. Scalici E, Bechoua S, Astruc K, Duvillard L, Gautier T, Drouineaud V, et al. Apolipoprotein B is regulated by gonadotropins and constitutes a predictive biomarker of IVF outcomes. Reprod Biol Endocrinol. 2016;14(1):28. https://doi. org/10.1186/s12958-016-0150-4
  41. Turchinets A, Uvarova E, Khashchenko E, Kumykova Z. Targetnaya terapiya sindroma polikistoznykh yaichnikov [Target therapy of polycystic ovary syndrome]. Meditsinskiy sovet. 2023;17(5):7-13. https://doi.org/10.21518/ ms2023-060
  42. Pizzo A, Laganà AS, Barbaro L. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS. Gynecol Endocrinol. 2013;30(3):205-8. https://doi.org/10.3109/09513590.2013 .860120
  43. Zacchè MM, Caputo L, Filippis S, Zacchè G, Dindelli M, Ferrari A. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol. 2009;25(8):508-13. https://doi. org/10.1080/09513590903015544
  44. Minozzi M, D’Andrea G, Unfer V. Treatment of hirsutism with myo-inositol: A prospective clinical study. Reproductive BioMedicine Online. 2008;17(4):579-82. https://doi.org/10.1016/j.rbmo.2025.105271
  45. Greff D, Juhász AE, Váncsa S, Váradi A, Sipos Z, Szinte J, et al. Inositol is an effective and safe treatment in polycystic ovary syndrome: A systematic review and meta- analysis of randomized controlled trials. Reprod Biol Endocrinol. 2023;21(1):10. https://doi.org/10.1186/s12958-023-01055-z
  46. Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med. 1999;340(17):1314-20. https://doi.org/10.1056/NEJM199904293401703
  47. Gerli S, Papaleo E, Ferrari A, Di Renzo GC. Randomized, double blind placebo- controlled trial: Effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci. 2007;11(5):347-54. https:// doi.org/10.26355/eurrev_202309_33752
  48. Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myo-inositol in women with PCOS: A systematic review of randomized controlled trials. Gynecol Endocri- nol. 2012;28(7):509-15. https://doi.org/10.3109/09513590.2011.650660
  49. Unfer V, Carlomagno G, Rizzo P, Raffone E, Roseff S. Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles: A prospective, controlled, randomized trial. Eur Rev Med Phar- macol Sci. 2011;15(4):452-7.
  50. Dobrokhotova YuE, Gromova OA, Dukhanin AS, Kumykova ZKh, Sheremetyeva EV, Tabeeva GI. Inozitoly: farmakologiya i dannye klinicheskikh issledovaniy. Sovremennoe sostoyanie voprosa i perspektivy [Inositols: Pharmacology and findings of clinical trials. Current evidence and prospects]. RMZh. Mat' i ditya. 2022;5(4):309-19. https://doi.org/10.32364/2618-8430-2022-5-4-309-319
  51. Januszewski M, Issat T, Jakimiuk AA, Santor-Zaczynska M, Jakimiuk AJ. Metabolic and hormonal effects of a combined myo-inositol and D-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS). Ginekologia Polska. 2019;90(1):7-10. https://doi.org/10.5603/GP.2019.0002
  52. Artini PG, Di Berardino OM, Papini F, Genazzani AD, Simi G, Ruggiero M, et al V. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol Endocrinol. 2013;29(4):375-9. https:// doi.org/10.3109/09513590.2012.743020
  53. Jethaliya H, Gajjar N, Patel V, Deshpande S, Patel R. Efficacy of myo-inositol on anthropometric, metabolic, and endocrine outcomes in PCOS patients: A meta- analysis of randomized controlled trial. Reprod Sci. 2022;29(8):2282-98. https:// doi.org/10.1007/s43032-022-00933-y
  54. Fitz V, Graca S, Shruthi Mahalingaiah, Liu J, Lai L, Butt A, et al. Inositol for polycystic ovary syndrome: A systematic review and meta-analysis to inform the 2023 update of the international evidence-based PCOS guidelines. J Clin Endocri- nol Metab. 2024;109(12):2365. https://doi.org/10.1210/clinem/dgae588
  55. Plows J, Stanley J, Baker P, Reynolds C, Vickers M. The pathophysiology of gestational diabetes mellitus. Int J Mol Sci. 2018;19(11):3342. https://doi. org/10.3390/ijms19113342
  56. Christos C, Paolo C, Alexandros S. Gestational diabetes mellitus pharmacological prevention and treatment. Current Pharmaceutical Design. 2021;27(36): 3833- 40. https://doi.org/10.2174/1381612827666210125155428
  57. Zhang Z, Zhou Z, Li H. The role of lipid dysregulation in gestational diabetes mellitus: early prediction and postpartum prognosis. J Diabetes Investig. 2023;15(1):15-25. https://doi.org/10.1111/jdi.14119
  58. International Diabetes Federation. Global Diabetes Data Report 2010 — 2045. diabetesatlas.org. 2021. Available from: https://diabetesatlas.org/data/en/ world/
  59. Mistry SK, Das Gupta R, Alam S, Kaur K, Shamim AA, Puthussery S. Gestational diabetes mellitus (GDM) and adverse pregnancy outcome in South Asia: A systematic review. Endocrinol, Diabet Metab. 2021;4(4):285. https://doi. org/10.1002/edm2.285
  60. Hildén K, Magnuson A, Hanson U, Simmons D, Fadl H. Trends in pregnancy outcomes for women with gestational diabetes mellitus in Sweden 1998-2012: A nationwide cohort study. Diabet Med. 2020;37(12):2050-7. https://doi. org/10.1111/dme.14266
  61. Lende M, Rijhsinghani A. Gestational diabetes: Overview with emphasis on medical management. Int J Environ Res Public Health. 2020;17(24):9573. https:// doi.org/10.3390/ijerph17249573
  62. Diabetes. www.who.int. 2024. Available from: https://www.who.int/ru/news- room/fact-sheets/detail/diabetes
  63. Fetita LS, Sobngwi E, Serradas P, Calvo F, Gautier JF. Consequences of fetal exposure to maternal diabetes in offspring. J Clin Endocrinol Metab. 2006;91(10):3718-24. https://doi.org/10.1210/jc.2006-0624
  64. Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358(19):1991-2002. https://doi.org/10.1056/NEJMoa0707943
  65. Scholtens DM, Kuang A, Lowe LP, Hamilton J, Lawrence JM, Lebenthal Y, et al. Hyperglycemia and adverse pregnancy outcome follow-up study (HAPO FUS): Maternal glycemia and childhood glucose metabolism. Diabet Care. 2019;42(3):381-92. https://doi.org/10.2337/dc18-2021
  66. Klinicheskie rekomendatsii «Gestatsionnyy sakharnyy diabet» [Clinical Guidelines “Gestational Diabetes mellitus”]. Minzdrav.gov.ru. 2024. Available from: https:// cr.minzdrav.gov.ru/preview-cr/841_1
  67. U.S. National Library of Medicine. Clinicaltrials.gov [Internet]. Clinicaltrials.gov. Available from: https://clinicaltrials.gov/
  68. Vitale SG, Corrado F, Caruso S, Di Benedetto A, Giunta L, Cianci A, et al. Myo- inositol supplementation to prevent gestational diabetes in overweight non- obese women: Bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes – a randomized and open-label, placebo-controlled clinical trial. Int J Food Sci Nutr. 2020;72(5):670-9. https://doi.org/10.1080/096 37486.2020.1852191
  69. Esmaeilzadeh S, Ghadimi R, Mashayekh-Amiri S, Delavar MA, Basirat Z. The effect of myo-inositol supplementation on the prevention of gestational diabetes in overweight pregnant women: A randomized, double-blind, controlled trial. Min- erva Obstetrics and Gynecology. 2022;76(6):357-64. https://doi.org/10.23736/ S2724-606X.22.05036-9
  70. Asimakopoulos G, Pergialiotis V, Antsaklis P, Theodora M, Loutradis D, Daskalakis G. Effect of dietary myo-inositol supplementation on the insulin resistance and the prevention of gestational diabetes mellitus: An open-label, randomized controlled trial. Arch Gynecol Obstet. 2024;310(4):1895-903. https://doi. org/10.1007/s00404-024-07618-8
  71. Golivets T, Likrizon S, Dubonosova D. Insulinorezistentnost' kak prediktor polimorbidnosti. Patogeneticheskaya terapiya (obzor literatury) [Insulin resistance as a predictor of polymorbidity. Pathogenetic therapy (literature review)]. Aktual’nye problemy meditsiny. 2022;45(1):5-19. https://doi. org/10.52575/2687-0940-2022-45-1-5-19
  72. Celentano C, Matarrelli B, Pavone G, Vitacolonna E, Mattei PA, Berghella V, et al. The influence of different inositol stereoisomers supplementation in pregnancy on maternal gestational diabetes mellitus and fetal outcomes in high-risk patients: A randomized controlled trial. J Matern Fetal Neonatal Med. 2018;33(5):1-9. https://doi.org/10.1080/14767058.2018.1500545
  73. Quotah OF, Andreeva D, Nowak KG, Dalrymple KV, Almubarak A, Patel A, et al. Interventions in preconception and pregnant women at risk of gestational diabetes: A systematic review and meta-analysis of randomised controlled trials. Diabetol Metab Syndr. 2024;16(1):403-4. https://doi.org/10.1136/sti.62.6.403

Authors' information:

Druzhinina Anna Aleksandrovna,
Leading Expert of the Department of Medicines Safety Expertise, Scientific Centre for Expert Evaluation of Medicinal Products
ORCID ID: 0000-0001-6091-6449
E-mail: druzhininaaa@expmed.ru

Giulakhmedova Safiya Mirzabegovna,
Leading Expert of the Department of Medicines Safety Expertise, Scientific Centre for Expert Evaluation of Medicinal Products
ORCID ID: 0000-0001-9416-8135
E-mail: giulakhmedovasm@expmed.ru

Alyautdina Olga Sergeevna,
Doctor of Medical Sciences, Full Professor, Professor of the Department of Obstetrics and Gynecology No.1, Sechenov First Moscow State Medical University
ORCID ID: 0000-0003-0770-8020
E-mail: olasa@list.ru

Bashokouh Fatemeh,
Candidate of Medical Sciences, Head of Drugs and Controlled Medicines Division, Iran Food and Drug Administration
ORCID ID: 0000-0002-2509-0482
E-mail: fbashokouh@gmail.com

Eliseeva Ekaterina Maksimovna,
Expert of the Department of Medicines Safety Expertise, Scientific Centre for Expert Evaluation of Medicinal Products
E-mail: eliseevaem@expmed.ru
ORCID ID: 0009-0007-0566-7700

Chistokhina Anna Andreevna,
Category 2 Expert of the Department of Medicines Safety Expertise, Scientific Centre for Expert Evaluation of Medicinal Products
ORCID ID: 0009-0000-8907-1873
E-mail: chistokhina@expmed.ru

Information about support in the form of grants, equipment, medications

This study was conducted by funding from the Federal State Budgetary Institution Scientific Centre for Expert Evaluation of Medicinal Products, the Ministry of Health, Russian Federation part of the applied research funded under State Assignment No. 056-00001-25-00 (R&D Registry No. 124022300127-0)

Conflicts of interest: No conflict

Address for correspondence:

Druzhinina Anna Aleksandrovna
Leading Expert of the Department of Medicines Safety Expertise, Scientific Centre for Expert Evaluation of Medicinal Products

127051, Russian Federation, Moscow, 8/2 Petrovsky Blvd

Tel.: +7 (901) 7849166

E-mail: druzhininaaa@expmed.ru


This work is licensed under a Creative Commons Attribution 4.0 International License.

Materials on the topic:
  1. PROMOTING POSITIVE ATTITUDES TO BREASTFEEDING: WHAT ARE THE KEYS TO SUCCESS?
  2. MATERNAL OVERWEIGHT AND OBESITY AND RISK OF PRETERM DELIVERY
  3. THE IMPACT OF CONGENITAL UTERINE ANOMALIES ON PREGNANCY OUTCOMES
  4. THE IMPACT OF CHANGES IN HEMOSTASIS PARAMETERS ON THE PROBABILITY OF DEVELOPING FETAL GROWTH RETARDATION IN AVERAGE AND HIGH-RISK PREGNANT WOMEN
  5. PERINATAL OUTCOMES IN PATIENTS WITH EARLY AND LATE SEVERE PREECLAMPSIA
  6. EFFICACY OF EMERGENCY TRANSVAGINAL CERVICAL CERCLAGE
  7. PSYCHOLOGICAL IMPACT OF THE COVID-19 PANDEMIC ON PREGNANT WOMEN IN DUSHANBE
  8. HIGH-SENSITIVITY C-REACTIVE PROTEIN IN THE FIRST TRIMESTER OF PREGNANCY IN OBESE PATIENTS WITH GESTATIONAL DIABETES
  9. PREMATURE PLACENTAL ABRUPTION: EPIDEMIOLOGY, RISK FACTORS, AND MEDICAL AND SOCIOECONOMIC ASPECTS
  10. RATES AND CATEGORIES OF PRETERM BIRTHS IN MATERNITY CARE FACILITIES OF VARIOUS LEVELS

◄ Back to the list